Parameet Kumar

Parameet Kumar is a Senior Scientist at Emergent BioSolutions since June 2023, focusing on Raxibacumab, a monoclonal antibody for treating inhalation anthrax, and assisting in the validation process. Prior to this role, Kumar served as Scientist II in Analytical Development at NOVAVAX INC, contributing to the development of new assays and the analytical method transfer for SARS-CoV-2 vaccine production. Previous experience includes positions at Catalent Pharma Solutions and the Uniformed Services University, where notable achievements include leading research on the NEAT1 long non-coding RNA in cystic fibrosis and developing cell-based assays for gene therapies. Kumar's early research involved postdoctoral fellowships at The Johns Hopkins University and other institutions, focusing on microRNA analysis and mTOR signaling. Educational qualifications include a Ph.D. in Tuberculosis from the All India Institute of Medical Sciences and a Master's degree in Biotechnology from the Indian Institute of Technology, Roorkee.